Delivery Order SPE2DR25D2216-SPE2DR26F7UP7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,499.80 to AmerisourceBergen Drug Corp for Enbrel 25 mg/0.5 mL syringes on December 10, 2025, with completion targeted for December 11, 2025. This firm fixed-price, competitively awarded delivery order represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency awarded a $17,437.55 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of December 10, 2025. This is a firm fixed price contract with no set-aside designation, performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitive award under the company's existing relationship with the federal government. This delivery order is issued under...
- The Defense Logistics Agency awarded a competitive delivery order valued at $36,125.91 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of November 4, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $70,857.49 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This firm fixed price, competitively awarded contract was executed on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the open competitive procurement process through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Enbrel 50 mg/ml syringes, with a contract ceiling value of $9,651.82. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the vendor's...
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $13,078.04 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes. This competitively awarded, firm fixed-price delivery order was issued on December 2, 2025, with an ultimate completion date of December 3, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $13,737.99 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of September 12, 2025. This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and operates as a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $9,806.98 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes, with an ultimate completion date of September 17, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The contract was executed on September 16, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters....
- SPE2DR25D2216Indefinite Delivery Contract
- SPE2DR25D2216-SPE2DR26F7UP7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $42,400.52 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This firm fixed-price, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's substantial pharmaceutical supply relationship with the federal government, specifically supporting the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Enbrel, a biologic immunosuppressant medication used to treat autoimmune conditions, falls within the company's extensive portfolio of specialty medications and brand-name drugs delivered through the DLA's Medical Supply Chain to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.4k | 12/16/25 |